Trastuzumab deruxtecan
Enhertu · Antibody-drug conjugate (HER2/DXd)
Emerging AKI/proteinuria reports — under-published.
Gleevec · IMA
BCR-ABL TKI · approved 2001 · 9 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
The pioneering BCR-ABL TKI, with fluid retention, a slow eGFR drift, and uncommon proximal tubular (Fanconi-type) injury.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Periorbital/peripheral edema and fluid retention are common. Clinically meaningful renal injury is uncommon: long-term front-line imatinib is associated with a modest, measurable decline in eGFR over years, while proximal tubular dysfunction (hypophosphatemia, aminoaciduria, rare Fanconi syndrome) and AKI (including rare urate nephropathy from disease cytoreduction) are described at the case level.Source: Molica et al., Ann Hematol 2018 (front-line TKI eGFR cohort)
Tubular dysfunction and eGFR decline develop over months to years (edema is early).
Distilled from: “Edema early; tubular dysfunction and eGFR decline develop over months to years.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
TKI-associated AKI in ~4% of a CML cohort, incidence highest with imatinib vs dasatinib/nilotinib
Case-level: partial Fanconi syndrome with urinary phosphate loss / hypophosphatemia reported on long-term imatinib PMID 18215707 (opens PubMed in a new tab)
Tap a signature to trace where it strikes the nephron.
Electrolyte Disturbance strikes: Distal Tubule / Collecting Duct.
Electrolyte Disturbance
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
First-generation tyrosine kinase inhibitor that occupies the ATP-binding pocket of BCR-ABL1 (and c-KIT and PDGFR), blocking constitutive kinase signaling that drives leukemic and stromal-tumor proliferation. Used in chronic myeloid leukemia, Ph+ ALL, and GIST.
Class-level context for the major non-renal toxicities of the BCR-ABL TKI class.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Oct 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
The effect of renal impairment on the pharmacokinetics of imatinib was assessed in 59 patients with cancer and varying degrees of renal impairment at single and steady state imatinib doses ranging from 100 to 800 mg/day. The mean exposure to imatinib (dose normalized AUC) in patients with mild and moderate renal impairment increased 1.5- to 2-fold compared to patients with normal renal function. There are not sufficient data in patients with severe renal impairment [see Clinical Pharmacology (12.3) ]. Dose reductions are necessary for patients with moderate and severe renal impairment [see Dosage and Administration (2.12) ]. Table 17: Renal Function Classification Renal Dysfunction Renal Function Tests Mild CrCL Abbreviation: CrCL, creatinine clearance. = 40 to 59 mL/min Moderate CrCL = 20 to 39 mL/min Severe CrCL = less than 20 mL/min
Kidney rows of the label's dosage tables
From the IMKELDI label (Oct 2026) · DailyMed
No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 47,183 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
14,659 of 47,183 reports
Reported with hospitalization
8,334 of 47,183 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 2,964 of the 47,183 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Imatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Enhertu · Antibody-drug conjugate (HER2/DXd)
Emerging AKI/proteinuria reports — under-published.
Zanosar · Nitrosourea alkylator
Classic proximal tubular toxin → Fanconi and dose-limiting AKI.
Vidaza · Hypomethylating agent
Proximal (type 2) RTA / Fanconi-like tubulopathy; overt AKI uncommon.
Ogsiveo · Gamma-secretase inhibitor
2023 desmoid-tumor agent; phosphate/electrolyte disturbance.
Aqupla · Platinum agent
Second-gen platinum with reduced renal toxicity vs cisplatin.
Zometa · Bisphosphonate
Toxic ATN, infusion-rate dependent.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Imatinib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Imatinib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 97 clinical records among all 138 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.